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Abstract Accentuated right ventricular (RV) gradients in
action potential duration (APD) have been implicated in the
arrhythmogenicity observed in Brugada syndrome in
studies assuming that ventricular effective refractory peri-
ods (VERPs) vary in concert with APDs. The present
experiments use a genetically modified mouse model to
explore spatial heterogeneities in VERP that in turn might
affect conduction velocity, thereby causing arrhythmias.
Activation latencies, APDs and VERPs recorded during
programmed S1S2 protocols were compared in RVand left
ventricular (LV) epicardia and endocardia of Langendorff-
perfused wild-type (WT) and Scn5a+/− hearts. Scn5a+/− and
WT hearts showed similar patterns of shorter VERPs in RV
than LV epicardia, and in epicardia than endocardia.
However, Scn5a+/− hearts showed longer VERPs, despite
shorter APD90s, than WT in all regions examined. The pro-
and anti-arrhythmic agents flecainide and quinidine in-
creased regional VERPs despite respectively decreasing
and increasing the corresponding APD90s particularly in
Scn5a+/− RVepicardia. In contrast, Scn5a+/− hearts showed
greater VERP gradients between neighbouring regions,
particularly RV transmural gradients, than WT (9.1±1.1 vs.
5.7±0.5 ms, p<0.05, n=12). Flecainide increased (to 21±
0.9 ms, p<0.05, n=6) but quinidine decreased (to 4.5±
0.5 ms, p<0.05, n=6) these gradients, particularly across the
Scn5a+/− RV. Finally, Scn5a+/− hearts showed greater con-
duction slowing than WT following S2 stimuli, particularly
with flecainide administration. Rather than arrhythmogenesis
resulting from increased transmural repolarization gradients
in an early, phase 2, reentrant excitation mechanism, the
present findings implicate RV VERP gradients in potential
reentrant mechanisms involving impulse conduction slowed
by partial refractoriness.
Keywords Cardiac electrophysiology. Ventricular
fibrillation . Arrhythmia . Action potential . Sodium channel
Introduction
Brugada syndrome (BrS) is associated with decreased Na+
channel function and increased incidences of polymorphic
ventricular tachycardia (VT) and sudden cardiac death.
Although genetically heterogeneous, up to 30% of patients
have mutations in SCN5A, the only gene extensively
studied in connection with BrS which encodes the cardiac
Nav1.5 α-subunit [14]. Possible arrhythmogenic mecha-
nisms were initially modelled using canine wedge prepara-
tions; these, however, entailed pharmacological manoeuvres
with potentially nonspecific effects [51]. More recently,
heterozygotic Scn5a+/− hearts, showing 50% reductions in
their transmembrane Na+ currents, have reproduced features
of the human clinical condition, demonstrating STelevation
and enhanced arrhythmogenesis exacerbated by flecainide
and relieved by quinidine [26].
Both canine and murine cardiac systems have demon-
strated regions of shortened epicardial relative to endocar-
dial action potential durations (APDs). In particular, murine
Scn5a+/− hearts have demonstrated increased transmural
APD gradients [27] and increased incidences of alternans,
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particularly in the right ventricle (RV) [29], following
flecainide administration. This localized AP shortening
could potentially result in losses of the AP dome, thereby
altering repolarization gradients within or across the
myocardial wall. This could increase the likelihood of early
epicardial ‘phase II’ re-excitation as a key arrhythmic
mechanism in BrS. At the very least, such a mechanism
could coexist with arrhythmic tendencies resulting from the
altered conduction also expected from the loss of Na+
channel function in BrS [30].
However, early reentry mechanisms would specifically
require corresponding reductions in the epicardial refractory
periods. Certainly, normal canine [12, 15] and human [22]
hearts show closely related APDs and ventricular effective
refractory periods (VERPs), with a recovery of excitability
consistently occurring at ~85% repolarization over a wide
range of steady-state cycle lengths. However, VERPs can
be selectively affected by factors that need not similarly
affect APD. These include the numbers, and time courses of
activation or inactivation, of Na+ and K+ channels; the
amplitude and duration of the applied stimuli [46]; and
conditions of myocyte damage or ischaemia. Na+ channel
dysfunction therefore could well alter VERP differently
from APD. Contrasting APD and VERP changes also occur
under other arrhythmogenic circumstances, as in hypoka-
laemia [42]. Conflicting results concerning VERP durations
in BrS have been reported in previous clinical studies [2]
and experiments in cell expression lines (for references, see
[6]).
However, systematic regional studies of VERPs have not
hitherto been performed in either genetic or pharmacolog-
ical BrS models. Thus, it has often implicitly been assumed
that VERPs and APDs vary concordantly in both wild-type
(WT) and BrS. However, murine Scn5a+/− hearts have been
previously reported to show either similar [44] or greater
[35] VERPs than WT hearts, depending on their specific
arrhythmogenic properties. Both loss-of function Na+
channel mutations and pharmacological Na+ blocking
agents such as flecainide and quinidine might be expected
to increase VERP. If AP firing requires a critical number of
Na+ channels, a greater relative proportion would then be
required to recover from refractoriness, and this would
occur later in the repolarization phase.
The present experiments specifically assess the roles of
VERPs and conduction latencies in arrhythmogenesis in
Scn5a+/− hearts. They go on to compare these parameters in
the RV and LV epicardium and endocardium following the
introduction of flecainide or quinidine for the first time.
These agents are used respectively to unmask ventricular
arrhythmogenesis in otherwise asymptomatic BrS patients
[7] and to achieve protective actions in symptomatic BrS
[5]. VERP changes, whether by themselves or relative to
those of APD, could well affect arrhythmogenicity, whether
by altering AP recovery or affecting conduction character-
istics. In the first case, arrhythmogenic mechanisms
involving early, phase II, reentrant excitation, previously
suggested for BrS [51], would require reductions in VERPs,
at least in relation to APD. In the second, spatial differences
in VERP, and the consequences of these for conduction,
may remain critical to the initiation of reentrant arrhythmia
in BrS. Clarifying such distinctions may be important to
future work investigating possible pharmacological man-
agement for a condition for which current treatment
primarily involves ICD implantation.
Materials and methods
Mice aged 4–8 months were obtained from breeding pairs
of heterozygote Scn5a+/− and WT inbred 129/sv mice,
initially supplied by Harlan (UK). The experiments used a
Langendorff-perfused preparation adapted for the murine
heart [4]. Perfusion of bicarbonate-buffered Krebs-
Henseleit solution was maintained at a flow rate of 2–
2.5 ml min−1 using a peristaltic pump (Watson-Marlow
Bredel pumps model 505S, Falmouth, Cornwall, UK), and
warmed and maintained at 37°C via a water jacket and
circulator (Techne model C-85A, Cambridge, UK). Initial
experiments using a thermometer probe placed on the
epicardial or endocardial surfaces confirmed that a temper-
ature of 37°C was reached in both regions. Where used,
flecainide and quinidine (Sigma-Aldrich, Poole, UK)
dissolved in buffer solution were perfused for 15 min prior
to and throughout data acquisition at concentrations within
the same range as known clinical therapeutic levels used in
BrS (flecainide, 0.2–0.9 mg l−1; quinidine, 1.0–3.0 mg l−1)
[38].
Monophasic action potentials (MAPs) were recorded
using electrodes constructed from two pieces of galvani-
cally chlorided, Teflon-coated, 0.25-mm diameter silver
wire twisted together to form one contact electrode and one
reference electrode. This was either placed against the
cardiac surface for epicardial recordings or introduced into
the ventricular cavity through a small access window
created in the ventricular wall for endocardial recordings.
Care was taken to avoid regional stretch by manipulation,
especially at the thin RV wall. MAP signals were amplified
and band-pass filtered between 0.1 and 300 Hz (Neurolog
AC amplifiers and filters models NL104 and NL125/6,
respectively; Digitimer, Welwyn Garden City, Herts, UK),
then digitized using a 1401plus interface (Cambridge
Electronic Design, Cambridge, Cambs., UK). Paired plat-
inum stimulating electrodes were used to pace the heart.
Hearts underwent a programmed electrical stimulation
(PES) technique of a 5-min period of 8-Hz regular pacing
followed by cycles of a decremental paced electrogram
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sequence comprising an eight-beat stimulus (S1) drive train
at 8 Hz followed by an extra-stimulus (S2). The S1–S2
interval was reduced by 1 ms between successive drive
trains until the preparation became either refractory or
arrhythmic (Fig. 1a). The incidence of arrhythmogenesis
was defined as the presence of VT lasting more than 1 s in
any given trace. MAP waveforms were then analysed using
Spike2 software (Cambridge Electronic Design). The point
of maximum positive deflection was considered the point of
0% repolarization; that of full return to baseline of 100%
repolarization. The APD during regular pacing was mea-
sured at 90% repolarization, APD90, as shown in Fig. 1b.
Activation latencies were calculated as the time from
stimulus to the point of maximum positive deflection of
the MAP waveform. L1 was defined as the activation
latency following an S1 stimulus and L2 as the activation
latency following the last S2 able to elicit an AP.
The VERP was also measured from the PES sequences.
As explained in “Results,” two independent measures of
VERP were obtained. Firstly, VERP at the stimulus site was
determined from the S1S2 interval at which the S2 stimulus
last excited an action potential (VERPs). Second, VERP at
the recording site was determined from the time interval
between AP upstrokes in response to the S1 and S2 stimuli
at the S1S2 interval immediately preceding S2 refractoriness
(VERPr).
For the majority of experiments, in order to isolate
measurements of VERP from the effects of conduction
velocity, the heart was stimulated at the point of the
recording electrode. The VERPs was used in these measure-
ments as MAPs recorded close to the stimulus site
unavoidably contained stimulus artefact and rendered the
VERPr difficult to measure accurately. We thus consider our
recording configuration to have achieved a situation similar
to earlier studies that delivered S2 stimuli through the
recording electrode and determined VERP from the
upstroke of the last AP (rather than the S1 stimulus) to
the upstroke resulting from the S2, which is usually
synchronous with the S2 stimulus as they are at the same
position [16].
In our final set of experiments, in order to investigate
relationships between the VERP and the activation latency,
we changed our protocol to pace at sites further from the
recording electrode. In these experiments, the stimulating
electrode and the epicardial LVand RV recording electrodes
were clamped either 5 or 10 mm apart from each other.
Endocardial MAPs could not be recorded in this way as the
position of the endocardial electrodes within the ventricular
cavity could not be fixed to this accuracy.
Care was taken to ensure that the stimulus potential
applied was always kept at twice that of the threshold
voltage to produce capture as stimulus intensity has a
significant effect on VERP in itself [34]. The relationship
between APD and VERP was calculated as the ratio
between the two: VERP/APD. Transmural gradients of
VERP were calculated as the difference (ΔVERP) between
the endocardial and epicardial VERP values, i.e. (endocar-
dial VERP) − (epicardial VERP), and transventricular
gradients as the difference between RV and LV VERP
values in the epicardium and endocardium.
Fig. 1 Typical RV epicardial MAP recordings from a Scn5a+/− heart
during the programmed stimulation (S1S2) protocol. a Recording
showing the point of refractoriness (asterisk) where the S2 stimulus
fails to elicit a response. The equally spaced vertical markers below
each trace indicate S1 stimulus timings, with the extra vertical
markers indicating S2 extra-stimuli. b Diagram illustrating measure-
ment of: APD90, L1 (latency following S1 stimulus), L2 (latency
following S2 stimulus), VERPs (VERP at stimulus site) and the
VERPr (VERP at recording site). c Recordings illustrating a situation
in which the pacing and recording electrodes are adjacent (top trace)
and a situation where the heart is paced from a site remote from the
recording site (bottom trace). In the top trace VERPs and VERPr are
23 and 25 ms, respectively, whilst in the bottom trace, the VERPs is
24 ms and the VERPr is 53 ms
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Twelve WT and 12 Scn5a+/− mice were used in all
experiments, with half of each group eventually exposed to
flecainide and half to quinidine. These results were
expressed as mean±SEM values. Differences in activation
latencies, APDs and VERPs, and gradients and ratios of the
two, were analysed using ANOVA with post hoc Tukey’s
honestly significant different tests. Differences in arrhyth-
mia incidences were analysed using Fisher’s exact tests.
Correlations between arrhythmia incidence and VERP
gradients were analysed using Pearson’s correlation. A
p value of <0.05 was taken as a criterion for significance.
Results
VERP measurements are dependent upon the relationship
between stimulus and recording site
As explained in “Materials and methods,” the VERP was
measured from the PES sequences. The VERP is tradition-
ally measured as the shortest S1S2 time at which an S2 AP
is recordable. It is therefore a function of the S1 and S2
stimulus times at the point of stimulation. However, for an
AP to be detected by the recording electrode, the refractory
period must have been exceeded throughout the tissue
intervening between the sites of stimulation and recording.
Thus, the VERP that is measured reflects the refractory
time course in the entire line of tissue between the two. For
this reason, the VERP is usually longer if pacing and
stimulation are at different locations on the heart.
Previous studies in murine models have often adopted
points of stimulation and recording on opposite, left and right,
ventricles [42, 44]. This could account for previous reports
of poor in vivo correlations between APD, measured at a
single recording site by MAP catheter, and VERP, measured
by a separate pacing catheter, that might reflect known
variabilities of both APD and VERP between different
ventricular sites, as well as differences in conduction velocity
[16]. This issue led us to obtain two independent measures
of VERP. Firstly, VERP at the stimulus site was determined
from the S1S2 interval at which the S2 stimulus last excited
an action potential (VERPs). Second, VERP at the recording
site was determined from the time interval between AP
upstrokes in response to the S1 and S2 stimuli at the S1S2
interval immediately preceding S2 refractoriness (VERPr).
However, if the stimulation and recording sites are far
apart, the VERPr is further likely to be overestimated as the
conduction velocity of the action potential resulting from
the S2 stimulus is slowed as it passes through tissue in a
relative refractory state, and therefore L2 is greater than L1.
From Fig. 1c, we can see that:
VERPr ¼ VERPs þ L2 L1ð Þ
Therefore, we conducted measurements of both VERPs
and VERPr at successively closer distances between
stimulating and MAP recording electrodes. With decreasing
interelectrode spacings, the VERPr reached a constant value
in a given heart and converged with the VERPs to become
statistically indistinguishable.
The increased arrhythmogenicity in Scn5a+/− hearts
is accompanied by increased rather than decreased VERP
The programmed electrical stimulation procedures adopted
here confirmed that Scn5a+/− hearts were more arrhythmo-
genic than WT (21% of traces vs. 6%, p<0.01, n=12) and
that this tendency was increased by flecainide (to 40%, p<
0.01, n=6) and decreased by quinidine (to 3%, p<0.01, n=
6). This agreed with previous studies and established the
phenotypic background against which subsequent findings
could be compared [27, 44].
Figure 2 shows typical MAP recordings of the responses
following the last S2 stimuli that elicited APs and from
which APDs and VERPs could be calculated. The experi-
ments confirmed previous studies [27] in which the APD
was found to vary across regions of the heart so that the RV
epicardial APD was shorter than the LVepicardial APD, and
also shorter than the RVendocardial APD, thus setting up a
significant repolarization gradient across the RV (Fig. 3a).
Fig. 2 Typical recordings from the RVepicardium and endocardium of
a WT and a Scn5a+/− heart and from the Scn5a+/− heart after drug
treatment. The part of the recording showing the last S2 in the
programmed stimulation protocol which elicits an action potential is
shown in each case. Recordings have been synchronized with respect
to their S1 times to demonstrate the respective differences in VERPs
(as calculated from S2 − S1). The dotted vertical lines denote the S2
timings of the epicardium followed by that of the endocardium and
thus enable the difference between VERPs in the epicardium and
endocardium in a given heart to be more easily compared
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APDs of Scn5a+/− hearts were also shorter than the
corresponding APDs of WT hearts, and were shortened
by flecainide and lengthened by quinidine (Fig. 3b), in
agreement with previous findings in murine [27] and
pharmacological canine BrS models [20] as well as clinical
studies [21].
However, measurements of VERPs taken from the same
recordings were not in accord with predictions of reduced
refractoriness required for early reentry phenomena. In-
stead, they related the increased arrhythmogenicity in
Scn5a+/− with increased, rather than decreased, VERP and
the pro- and anti-arrhythmic effects of flecainide and
quinidine both with increased VERP. Firstly, despite the
greater arrhythmogenicity in Scn5a+/− compared with WT,
both variants showed similar patterns of shorter VERPs in
the RV than the LVepicardium (39.9±0.9 vs. 45.8±1.3 ms,
p<0.05, n=12 for Scn5a+/−) and in the epicardium than the
endocardium (39.9±0.9 vs. 49.9±1.9 ms, p<0.05, n=12 for
RV in Scn5a+/−; Fig. 3a). There were no endocardial
transventricular VERP gradients.
Secondly, these variations paralleled the corresponding
variations in APD, giving constant VERP/APD ratios
through all the recording sites (Fig. 3c). This was in
contrast to the greater arrhythmogenicity in the RV
suggested in earlier studies. Thirdly, again in contrast to
their greater arrhythmogenicity, Scn5a+/− hearts showed
systematically longer VERPs than WT in all cardiac
regions. Fourthly, the pro- and anti-arrhythmic agents
flecainide and quinidine both increased VERPs in both
WT and Scn5a+/− hearts in all regions, although the effect
was more pronounced with quinidine than flecainide (e.g.
39.9±0.9 ms before drug to 45.3±2.6 ms with flecainide
and to 73.3±1.5 ms with quinidine, p<0.05, n=6 for the
RV in Scn5a+/−; Fig. 3b). Finally, the larger VERP in the
face of smaller APD values resulted in larger VERP/APD
ratios in Scn5a+/− hearts than WT. All the mean VERP/APD
values were <1 for the WT hearts, but were >1 for the
Scn5a+/− hearts (e.g. 0.94±0.02 vs. 1.1±0.01, p<0.05, n=
12 for the RVepicardium).
The increased arrhythmogenicity in Scn5a+/− hearts
is accompanied by increased VERP gradients
Altered arrhythmogenicity, whether resulting from genetic
or pharmacological manipulations, instead correlated with
spatial variations in VERP. VERP gradients were explored
using a strategy similar to previous explorations of APD
gradients, as opposed to absolute APD values, between
neighbouring ventricular regions [27] (Fig. 4a). Such
differences are illustrated by comparing the MAP record-
ings in Fig. 2, which are synchronized to the timings of
their S1 stimuli to demonstrate their respective VERP
differences (as calculated from S2 − S1). The dotted
vertical lines denote the timings of the S2 stimuli and
demonstrate a greater transmural VERP gradient in
Scn5a+/− than WT hearts. Flecainide increased both the
mean VERP values and VERP gradients, whilst quinidine
increased the mean values but decreased the VERP
gradient.
The VERP gradients were greater across the RVs than
the LVs in both Scn5a+/− and WT (e.g. 9.1±1.1 vs. 4.7±
0.5 ms, p<0.05, n=12 for Scn5a+/−). They were also greater
in Scn5a+/− than WT hearts (e.g. 9.1±1.1 vs. 5.7±0.5 ms,
p<0.05, n=12 for RV; Fig 4b). Furthermore, epicardial
transventricular VERP gradients were greater in Scn5a+/−
than WT (5.9±0.5 vs. 4.0±0.4 ms, p<0.05, n=12). Despite
their respective pro- and anti-arrhythmic effects, treatment
with either flecainide or quinidine did not affect ΔVERP
values in the WT, apart from relatively small but still
statistically significant increases in RV transmural gradient
with flecainide (5.7±0.5 vs. 9.8±1.1 ms, p<0.05, n=6). In
contrast, they exerted more noticeable effects particularly in
the RV of Scn5a+/− hearts, where the ΔVERP was
significantly increased (from 9.1±1.1 to 21±0.9 ms, p<
Fig. 3 a VERP and APD90 in four cardiac regions; n=12 for both WT
and Scn5a+/−. *Significant values of t tests between WTand Scn5a+/−.
†Significant values of t tests between cardiac regions within WT and
Scn5a+/− hearts (black, VERP; grey, APD). b VERP and APD90 in the
RVepicardium before and after drug exposure; n=12 prior to drug and
n=6 in all cases following drug. *Significant values of t tests
comparing values before and after drug administration (black, VERP;
grey, APD). c VERP/APD90 in four cardiac regions; n=12 for both
WT and Scn5a+/−. *Significant values of t tests between WT and
Scn5a+/−
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0.05, n=6) by flecainide and significantly decreased (to 4.5±
0.5 ms, p<0.05, n=6) by quinidine (Fig. 4c).
Such increases in VERP gradient correlated with
increased arrhythmogenicity. Figure 5a shows a typical
recording from the RV epicardium of a Scn5a+/− heart
showing the initiation of VT by an S1S2 protocol.
Figure 5b plots the values of RV transmural ΔAPD90 and
ΔVERP against percentage incidences of arrhythmia
recorded in both WT and Scn5a+/− hearts, before and after
the addition of flecainide or quinidine. Linear fits can be
constructed for both relationships, but ΔVERP has a very
strong correlation with arrhythmogenic incidence, with a
Pearson’s coefficient of 0.970, whilst the coefficient for
ΔAPD90 is only 0.731. Whilst these differences in
correlation alone do not exclude a role for repolarization
gradients in the ventricular arrhythmogenicity observed in BrS,
they do support a scheme implicating regional differences in
VERP rather than mean VERP values.
The increased VERPs in Scn5a+/− hearts are accompanied
by increased latencies in activation by S2 stimuli
The final experiments correlated the increased VERPs in
Scn5a+/− with increased slowing in the conduction follow-
ing S2 stimuli, particularly following the addition of
flecainide. The previous experiments, which had used
closely placed pacing and recording electrodes, were
modified by placing the electrodes on the same ventricle
but spaced 5 or 10 mm apart. Activation latencies at a 0-
mm interelectrode distance were all relatively short. Those
Fig. 4 a Four chambers of a typical Scn5a+/− heart are displayed
diagrammatically: left and right epicardium and endocardium, with
their respective VERP values in normal font. Arrows between the four
areas depict the gradients between them, with ΔVERP values in italic
font. Data are expressed as mean±SEM. b ΔVERP in four cardiac
regions; n=12 for both WTand Scn5a+/−. *Significant values of t tests
between WT and Scn5a+/−. †Significant values of t tests between
cardiac regions within WT and Scn5a+/−. c ΔVERP across the RV
before and after exposure to flecainide or quinidine; n=12 prior to
drug and n=6 in all cases following drug. *Significant values of t tests
comparing values before and after drug administration
Fig. 5 a Example recording from the RV epicardium of a Scn5a+/−
heart showing the initiation of VT during an S1S2 protocol. b Graph
plotting RV transmural ΔAPD90 and ΔVERP against the percentage
incidence of arrhythmia recorded in WT and Scn5a+/− hearts, before
and after flecainide or quinidine. A strong positive correlation exists
for ΔVERP (Pearson’s correlation=0.970). a WT before drug, b WT
after flecainide, c WT after quinidine, d Scn5a+/− before drug, e
Scn5a+/− after flecainide, f Scn5a+/− after quinidine
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in Scn5a+/− hearts were longer than those in WT hearts due
to the slower AP depolarization, seen in a slower rise time
of the MAP trace, as would be expected with a reduced
number of activatable Na+ channels. Recordings with the
increased interelectrode spacings showed larger activation
latencies as the distance through which the impulse had to
travel was larger (Fig. 6a, b). They also showed greater
differences between L2 and L1 (L2 − L1; Fig. 6c), as
expected from the effects of slowed conduction through the
partially refractory tissue, giving greater differences in
VERPs and VERPr, similar to the traces typified in
Fig. 1c. However, whilst in all cases the differences between
L2 and L1 increased as the interelectrode spacing increased,
this effect was more pronounced in the Scn5a+/− hearts than in
the WT hearts. Whilst the effect was similar between the LV
and RV in the WT hearts, it was more pronounced in the RV
than the LVof Scn5a+/− hearts. Flecainide and quinidine both
slightly exacerbated the L2 − L1 increase with distance in
WT hearts. However, in Scn5a+/− hearts, flecainide made the
L2 − L1 increase very much more markedly with distance,
whilst this effect was attenuated by quinidine. These final
experiments thus suggest a scheme in which variations in
VERP can act to produce arrhythmias through alterations in
conduction velocity.
Discussion
The present studies examining VERPs and conduction
latencies follow from recent findings of increased RV trans-
mural APD gradients in Scn5a+/− hearts [27], which might
predispose the epicardium to early, phase II, re-excitation.
The occurrence of these early re-excitation phenomena
suggested for BrS would require correspondingly early
recoveries from refractoriness. On the other hand, they
would be excluded by a combination of shortened APDs but
lengthened VERPs. The present experiments test these
possibilities for the first time.
WT and Scn5a+/− hearts both showed regional hetero-
geneities in VERPs, consistent with both clinical reports
[23] and known differences in outward Ito potassium
current [13, 45]. However, comparisons between WT and
Scn5a+/− hearts revealed contrasting rather than concordant
APD and VERP differences and associated the arrhythmo-
genic Scn5a+/− phenotype with greater rather than reduced
VERPs. Whilst these findings may seem surprising, they
are consistent with expectations from reduced numbers of
Na+ channels available for re-excitation in Scn5a+/− hearts.
The duration of refractoriness is dependent upon a recovery
of a critical number of activatable Na+ channels. A greater
relative proportion of such channels would then be required
to enable resumption of excitability, and this would occur
later in the repolarization phase. This hypothesis is
consistent with the present findings following Na+ reduc-
tion by genetic means in Scn5a+/− hearts or by pharmaco-
logical means through the effects of Na+ channel blockers.
Previous computational studies modelling situations of
reduced Na+ conductance [40, 43], as well as experimental
studies showing reduced Na+ conductance in ischaemic
tissue [39], have also demonstrated increased refractory
periods.
The pro- and anti-arrhythmic agents flecainide and
quinidine both increased regional VERPs. The effect was
more pronounced with quinidine than with flecainide,
probably due to the additional strong K+ channel-blocking
actions of quinidine, as opposed to flecainide whose
predominant effect is on Na+ channels without a significant
effect on K+ channels [50]. However, the action of both
drugs in increasing VERP is consistent with their known
effects in canine and rabbit preparations [8, 17], as well as
human hearts [36, 41]. Together, these findings associated
increased arrhythmogenicity in Scn5a+/− hearts with a
combination of shortened APDs but increased VERP. This
is in agreement with observations in isolated porcine hearts
in which flecainide exerted anti-arrhythmogenic properties in
tissue with short VERPs but pro-arrhythmic effects in tissue
Fig. 6 Graph of epicardial L1 (a) and L2 (b) and the time difference
between L2 and L1 (c) against the interelectrode distance. A second-
order polynomial is fitted to each relationship. a LV WT before drug, b
RV WT before drug, c LV Scn5a+/− before drug, d RV Scn5a+/− before
drug, e RV WTafter flecainide, f RV WTafter quinidine, g RV Scn5a+/−
after flecainide, h RV Scn5a+/− after quinidine
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with longer VERPs [9]. However, all these findings directly
conflict with a more established hypothesis, first proposed
following experiments in the canine pharmacological wedge
preparation where electrotonic forces between sites at which
the APD is maintained and those at which it is attenuated due
to loss of the AP dome can produce an extrasystole via local
re-excitation (phase 2 reentry), which in turn can initiate circus
movement reentry [51]. Whilst studies in the Scn5a+/− mice
have indeed shown increased repolarization gradients in the
RV [27], this proposed mechanism of early re-excitation
would require shortened VERPs to allow reentrant circuits to
flow and therefore would be unlikely to occur in the situation
of increased refractoriness seen in our study.
However, the findings remain compatible with an
important role of refractory periods, in particular their
spatial variations and the consequences of these for
conduction, in the initiation of reentrant arrhythmia in
BrS. We have shown a strong correlation between refractory
gradients and arrhythmia incidence in the Scn5a+/− mice.
This study cannot itself prove a causal link between the two
or demonstrate the underlying molecular mechanism;
however, similar arrhythmogenic effects of increased VERP
dispersion have been observed elsewhere in experiments in
genetic and pharmacological animal models of long QT
syndrome [3, 18], short QT syndrome [31] and ischemia
[19, 33], as well as modelling studies [47]. Similarly,
patients with long QT syndrome [49] and arrhythmic post-
infarct patients [32] also show greater dispersions of
refractory periods. Here, Scn5a+/− hearts showed greater
VERP gradients than WT, particularly across the RV,
compatible with differences in the sensitivity of membrane
potentials in areas of different K+ current density. Scn5a+/−
hearts also showed greater conduction slowing than WT
hearts following S2 stimuli, particularly following flecai-
nide treatment, in line with clinical findings [37]. Whilst
quinidine also increased the latencies both following S1 and
S2 stimuli, it did so to a lesser extent than flecainide, in
particular for L2. This is again likely to be due to the
relatively dominant effects of flecainide on the Na+ channel,
as opposed to quinidine’s stronger action on the K+
channel. Thus, whilst quinidine may have a larger effect
in increasing the refractory period itself, flecainide’s actions
in Na+ channel blockade leads to greater conduction
slowing and thus heterogeneity in tissue excitability and
refractoriness [50]. As well as being generated by refractory
heterogeneity, conduction slowing can also occur directly as a
result of Na+ channel dysfunction and resulting reduction in
AP depolarization velocity [48], which can add to the
likelihood of reentrant circuits being formed. It is furthermore
possible that the heterogeneities in our model are increased
by the presence of areas of local fibrosis, particularly in the
RV, as documented both in clinical cases of BrS [10] and in
the Scn5a+/− mouse model [48].
This study adds to a recent series of papers by our group
attempting to elucidate the mechanisms of arrhythmo-
genesis using a murine model of BrS. We have previously
demonstrated both depolarization abnormalities, in the form
of delayed conduction latencies [27] and slowed activation
patterns [25], and repolarization abnormalities, in the form
of heterogeneities in APDs and steep restitution curves with
high incidences of discordant alternans [24]. However, the
evidence in the present studies links these two mechanisms
by correlating the arrhythmic propensity shown by Scn5a+/−
hearts with reentrant arrhythmias attributable to enhanced
RV transmural refractory gradients, in turn leading to
slowed conduction. Our ‘loss-of-function’ Scn5a+/− hearts
show a 50% reduction in the early transmembrane Na+
current [35] that reduces the speed and amplitude of the
depolarization wave. Impulse propagation from S2 stimuli
is further reduced as the impulse travels through partially
refractory tissue. In situations of prolonged refractoriness,
impulses are increasingly likely to travel through tissue
which is still partially refractory. Therefore, heterogeneity
in tissue excitability of itself can promote tachycardias as a
result of slowed conduction and functional conduction
block, leading to wave breakup and reentrant excitation.
Our study could also be helpful in elucidating the role of
the ST elevation in the right precordial leads that is
characteristic of BrS and that is also seen in the Scn5a+/−
mice [26]. Opinion is currently divided as to whether the
ST elevation is caused by depression or loss of action
potential dome in the RVepicardium, creating a transmural
voltage gradient [1], or through a selectively slowed
conduction at the RVOT [37]. The mechanisms underlying
the ST elevation and the ventricular arrhythmogenesis are
generally assumed to be linked, particularly as both
phenomena are localized to the RV and in light of
observations of accentuated ST elevation immediately
preceding VF [28]. However, it is possible that whilst
transmural voltage gradients cause the ST elevation, it is in
fact associated with changes in refractory properties of the
tissue, and hence conduction slowing, which then leads to
the initiation of reentrant circuits.
The main limitations of the study are associated with the
use of a mouse model. Our model is a heterozygote for the
Scn5a gene, and we are therefore limited in investigating
the role of other voltage-gated ion channels, in particular
voltage-gated Ca2+ channels, which could also play a role
in triggering cardiac events in BrS patients. Secondly, the
small size of the mouse heart means that strong electrotonic
forces may act to minimize the effect of any spatial
heterogeneities that are created and reduce their potential
to create a reentrant substrate. The action potential
morphology differs between humans and mice as mice use
less L-type Ca2+ channel current, which means that the
mouse AP does not have a plateau phase and has a shorter
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APD [11]. This means that the spike and dome morphology
present in larger mammals is not present in our mouse
model. However, we were able to demonstrate a clear
propensity to arrhythmia in our BrS mouse model and
correlate this with enhanced RV transmural refractory
gradients despite these limitations.
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